(NASDAQ: BDTX) Black Diamond Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.92%.
Black Diamond Therapeutics's earnings in 2026 is $21,498,000.On average, 11 Wall Street analysts forecast BDTX's earnings for 2026 to be -$36,612,079, with the lowest BDTX earnings forecast at -$50,251,873, and the highest BDTX earnings forecast at -$11,366,495. On average, 10 Wall Street analysts forecast BDTX's earnings for 2027 to be -$56,809,686, with the lowest BDTX earnings forecast at -$74,819,456, and the highest BDTX earnings forecast at -$29,911,829.
In 2028, BDTX is forecast to generate -$45,215,291 in earnings, with the lowest earnings forecast at -$74,261,102 and the highest earnings forecast at -$22,134,754.